Zevra Therapeutics share price today

Zevra Therapeutics, Inc.'s share price was $11.17 at the close on 4 November 2026. That is 3.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $14, and at that close it sat 50% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running.

Over the last 1 year the share price moved −11% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Zevra Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Zevra Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Zevra Therapeutics, Inc. earned $8.4 M of net profit in the Jun 2026 quarter, −87.6% on the same quarter a year earlier. Full-year FY25 profit was $77.6 M. That is 21.2% of the quarter's revenue. The same quarter a year earlier earned $67.9 M. 8 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Zevra Therapeutics, Inc. reported $39.7 M of revenue in the Jun 2026 quarter, +53.3% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 38.8% a year on average. The last full year, FY25, came in at $106 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $136 M.

FY25 revenue was $106 M, +350.9% on the year before.

Recent pace: the last four quarters grew +229.9% on average, against 38.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +119.4%, against +139.7% a year over the last 8 quarters (rolling over).

Zevra Therapeutics, Inc.'s operating margin was 42.3% in the Jun 2026 quarter, 89.9 percentage points higher than the same quarter a year ago. Across 5 years it has been between −368.5% and 27.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +89.9 percentage points on the year while gross margin changed +44.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Zevra Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $1.6 M of cash, against $77.6 M of profit. After $835 K of spending on assets, free cash was −$2.4 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Zevra Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.2 M on assets over the last 3 years. Averaged over those years that is 0.4% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $1.2 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Zevra Therapeutics, Inc.'s P/E is 9.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Zevra Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Zevra Therapeutics, Inc. earned a ROE of 50% in FY25. That is up from a low of −266% in FY24. Its return on capital used (ROIC) is 80.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 72.9% net margin and 0.37× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 72.9% net margin × 0.37× asset turnover × 1.84× leverage (assets divided by equity) ≈ 49.6% on equity. The margin does most of the work; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 90.4% − 10.1% = +80.3 percentage points. The 10.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 90.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −14.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Zevra Therapeutics, Inc. has total debt of $1.5 M against shareholder equity of $218 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.41 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

11.6% of Zevra Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Zevra Therapeutics, Inc., the Z-score is 4.91. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 4.91 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Zevra Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Zevra Therapeutics is the 130th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Candel Therapeutics, Inc., 4D Molecular Therapeutics, Inc. and Kura Oncology, Inc. Just below it: Lexicon Pharmaceuticals, Inc., SL Science Holding and DBV Technologies S.A.

Biotechnology companies close in size

127. Candel Therapeutics, Inc. $692 million
128. 4D Molecular Therapeutics, Inc. $678 million
129. Kura Oncology, Inc. $677 million
130. Zevra Therapeutics, Inc. $665 million
131. Lexicon Pharmaceuticals, Inc. $659 million
132. SL Science Holding Limited $633 million
133. DBV Technologies S.A. $622 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

2705. MFA Financial, Inc. $668 million · REIT - Mortgage
2706. Mativ Holdings, Inc. $668 million · Specialty Chemicals
2707. Zevra Therapeutics, Inc. $665 million
2708. Tron Inc. $664 million · Leisure
2709. Lightwave Logic, Inc. $663 million · Specialty Chemicals

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.